| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 120.24 | 2.54 (+2.16%) | 58.53 - 131.82 | 1.8 million (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 118.28 |
|---|---|
| Previous Close | 117.70 |
| Day's Range | 117.72 - 120.45 |
| Market Cap | 50.2B |
| Avg Volume (10 Day) | 3.0M |
| Price/Earnings (Trailing 12 Mo.) | 35.8x |
| Earnings Per Share (Trailing 12 Mo.) | 3.29 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals
PR Newswire - Tuesday 06/18/2013 8:00 AM ET
Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
Business Wire - Monday 06/17/2013 1:30 AM ET
Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease
Business Wire - Friday 06/14/2013 6:04 AM ET
Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
Business Wire - Thursday 06/13/2013 4:30 AM ET
Celgene Announces Additional $3.0 Billion Share Repurchase Program
Business Wire - Wednesday 06/12/2013 8:00 AM ET
Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)
Business Wire - Wednesday 06/12/2013 7:30 AM ET
Celgene Corporation to Webcast at Upcoming Investor Conference
Business Wire - Thursday 06/06/2013 8:00 AM ET
U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Business Wire - Wednesday 06/05/2013 1:00 PM ET
| CELG | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 14.19% | |
| Net Income Growth (1yr) | -1.68% | |
| Total Debt/Equity | 0.56 | |
| LT Debt/Equity | 0.50 | |
| Earnings Yield | 2.79% | |
| Price/Sales | 8.62 |
| Company | Last | Change |
|---|---|---|
| Biogen Idec Inc | 210.80 | +1.47% |
| Amgen Inc | 101.50 | +2.44% |
| Regeneron Pharmaceuticals Inc | 242.76 | +4.32% |
| Gilead Sciences Inc | 51.94 | +1.78% |
| Shire PLC | 98.31 | -0.03% |
Data is delayed by at least 15 min.